Malignant hyperthermia in Czechia and Slovakia

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	KLINCOVÁ Martina ŠTĚPÁNKOVÁ Dagmar SCHRÖDEROVÁ Ivana KLABUSAYOVÁ Eva OŠŤÁDALOVÁ Edita VALÁŠKOVÁ Iveta FAJKUSOVÁ Lenka ZÍDKOVÁ Jana GAILLYOVÁ Renata ŠTOURAČ Petr
Year of publication	2022
Type	Article in Periodical
Magazine / Source	British Journal of Anaesthesia
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://www.sciencedirect.com/science/article/abs/pii/S0007091222002422?via%3Dihub
Doi	http://dx.doi.org/10.1016/j.bja.2022.04.029
Keywords	Malignant hyperthermia; Czechia; Slovakia
Attached files	Malignant_hyperthermia_in_Czechia_and_Slovakia.pdf
Description	Malignant hyperthermia (MH) is a rare, hereditary, life-threatening pharmacogenetic disorder triggered by some commonly used anaesthetics: all halogenated volatile anaesthetics and the depolarising neuromuscular blocking agent succinylcholine.1 Despite progress in common knowledge, diagnostics, and dantrolene availability, MH is still considered a severe anaesthetic complication. Genes pathogenically connected with MH include RYR1, CACNA1S, and STAC3.2 Prevalence of RYR1 variants associated with MH differs between countries and geographical areas.3 There is one MH diagnostic centre in the Slavic part of Europe located in Brno, Czechia that serves both Czech and Slovak patients.
Related projects:	Prohloubení poznatků o etiopatogenezi Maligní hypertermie (MH) a zefektivnění diagnostického algoritmu MH pro českou populaci. Simulační trénink v identifikaci a prevenci kritických událostí v anesteziologii a intenzivní medicíně III. Protektivní plicní ventilace během celkové anestezie a intenzivní péče u pediatrických pacientů: retrospektivní studie III